Physician profile
Nessrene Doudar
NPI 1598536153
$2,890.41
in general payments reported to CMS, 2019-2025
20 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,501 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $816.86 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $631.17 | 2024-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $311.62 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $243.33 | 2024-2025 | Spravato |
| Corcept Therapeutics | $141.50 | 2024-2025 | Korlym |
| Abbvie INC. | $128.50 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $110.30 | 2024 | Voquezna |
| Pfizer INC. | $81.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $66.13 | 2024-2025 | |
| Dexcom, INC. | $58.69 | 2024-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $50.00 | 2024 | Contrave |
| Paratek Pharmaceuticals, INC. | $48.23 | 2025 | Nuzyra, Xhance |
| Xeris Pharmaceuticals, INC. | $47.32 | 2025 | Recorlev, Gvoke Hypopen |
| Esperion Therapeutics, INC. | $33.55 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $28.32 | 2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.68 | 2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $21.56 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $18.41 | 2024 | |
| Lilly USA, LLC | $16.29 | 2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $15.67 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nessrene Doudar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.